BridgeBio Pharma, Inc.BBIO
| Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | -289 | -505 | -586 | -485 | -653 | -543 |
|---|
| Stock-based compensation | 21 | 58 | 100 | 92 | 109 | 96 |
|---|
| Loss on extinguishment of debt | - | - | -3 | - | - | -27 |
|---|
| Accretion of debt | 2 | 18 | 6 | 9 | 9 | 16 |
|---|
| Depreciation and amortization | - | - | 6 | 7 | 6 | 6 |
|---|
| Noncash lease expense | - | - | 6 | 5 | 4 | 4 |
|---|
| Accrual of payment-in-kind interest on term loan | - | - | - | 14 | 10 | - |
|---|
| Net loss from equity method investments | -21 | - | - | - | - | -31 |
|---|
| Loss (gain) on deconsolidation of subsidiaries | - | - | - | - | -1 | 178 |
|---|
| Loss (gain) from investment in equity securities, net | - | - | 30 | -8 | 18 | 8 |
|---|
| Fair Value Of Shares Issued Under License Agreements | - | 6 | - | 5 | - | - |
|---|
| Loss on sale of certain assets | - | - | - | -6 | - | - |
|---|
| Impairment of long-lived assets | - | - | - | 13 | - | 0 |
|---|
| Gain from sale of priority review voucher, excluding transaction costs | - | - | - | 110 | - | - |
|---|
| Gain from recognition of receivable from licensing and collaboration agreement | - | - | - | 13 | - | - |
|---|
| Other noncash adjustments, net | -1 | -3 | -7 | -1 | -0 | 3 |
|---|
| Accounts receivable | - | - | - | - | - | 3 |
|---|
| Receivables from licensing and collaboration agreements | - | - | 20 | -15 | -15 | - |
|---|
| Prepaid expenses and other current assets | 13 | 7 | 4 | -8 | 3 | 14 |
|---|
| Other assets | 17 | 2 | 10 | -11 | 2 | -2 |
|---|
| Accounts payable | -5 | -1 | 3 | -0 | 3 | 2 |
|---|
| Accrued compensation and benefits | 9 | 9 | 7 | -2 | 8 | 17 |
|---|
| Accrued research and development liabilities | 12 | 6 | 11 | -4 | -10 | 9 |
|---|
| Operating lease liabilities | - | - | -6 | -6 | -5 | -6 |
|---|
| Deferred revenue | - | - | - | 15 | -5 | 22 |
|---|
| Accrued professional and other liabilities | 2 | 8 | 12 | -3 | 4 | 4 |
|---|
| Net cash used in operating activities | -254 | -400 | -498 | -419 | -528 | -521 |
|---|
| Purchases of marketable securities | 213 | 288 | 590 | 137 | 30 | 94 |
|---|
| Maturities of marketable securities | - | 249 | 380 | 480 | 83 | 95 |
|---|
| Purchases of investments in equity securities | - | - | - | 56 | 108 | 20 |
|---|
| Proceeds from Sale of Equity Securities, FV-NI | - | - | - | 53 | 111 | 63 |
|---|
| Proceeds from Equity Method Investment, Distribution, Return of Capital | - | - | - | - | - | 26 |
|---|
| Payment for an intangible asset | - | - | 35 | 2 | - | 8 |
|---|
| Proceeds from sale of certain assets | - | - | - | 10 | - | - |
|---|
| Purchases of property and equipment | 3 | 8 | 13 | 5 | 1 | 1 |
|---|
| Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries | - | - | - | - | 1 | 0 |
|---|
| Net cash provided by investing activities | -217 | -53 | -201 | 453 | 54 | 61 |
|---|
| Proceeds from royalty obligation under Funding Agreement | - | - | - | - | - | 500 |
|---|
| Issuance costs and discounts associated with royalty obligation under Funding Agreement | - | - | - | - | - | 28 |
|---|
| Proceeds from Debt, Net of Issuance Costs | 37 | - | 456 | - | - | 450 |
|---|
| Issuance costs and discounts associated with term loan under Amended Financing Agreement | - | 13 | 16 | - | - | 16 |
|---|
| Repayment of term loans | - | - | 124 | 20 | - | 473 |
|---|
| Proceeds from Issuance of Common Stock | - | - | - | 5 | 144 | 315 |
|---|
| Proceeds from Stock Plans | 1 | 1 | 4 | 3 | 3 | 5 |
|---|
| Proceeds from Stock Options Exercised | 2 | 13 | 17 | 1 | 6 | 4 |
|---|
| Transactions with noncontrolling interests | - | - | - | - | -1 | - |
|---|
| Repurchase of RSU shares to satisfy tax withholding | - | 1 | 5 | 2 | 7 | 8 |
|---|
| Other financing activities | - | - | - | 1 | - | - |
|---|
| Net cash provided by (used in) financing activities | 399 | 447 | 736 | -13 | 452 | 748 |
|---|
| Net increase (decrease) in cash, cash equivalents and restricted cash | -72 | -6 | 38 | 21 | -22 | 289 |
|---|
| Cash paid for interest | 6 | 15 | 30 | 54 | 61 | 91 |
|---|
| Unpaid property and equipment | - | 1 | 1 | 0 | 0 | 0 |
|---|
| Transfers to noncontrolling interests | -29 | 12 | -2 | -4 | -11 | -6 |
|---|
| Payment-in-kind interest added to principal of term loan | - | - | - | 2 | - | - |
|---|